Efficacy of dual-functional liposomes containing paclitaxel for treatment of lung cancer Retraction in /10.3892/or.2017.6006

Wang,Rong-Hua; Cao,Hong-Mei; Tian,Zhi-Ju; Jin,Bo; Wang,Qing; Ma,Hong; Wu,Jing

doi:10.3892/or.2014.3644

Efficacy of dual-functional liposomes containing paclitaxel for treatment of lung cancer

Retraction in: /10.3892/or.2017.6006

Authors:
- Rong-Hua Wang
- Hong-Mei Cao
- Zhi-Ju Tian
- Bo Jin
- Qing Wang
- Hong Ma
- Jing Wu
View Affiliations

Affiliations: Department of Cardiothoracic Surgery, People’s Hospital of Zhangqiu, Zhangqiu, Shandong 250200, P.R. China, Pharmacy Intravenous Admixture Services, People’s Hospital of Zhangqiu, Zhangqiu, Shandong 250200, P.R. China, Department of Orthopedic Surgery, People's Hospital of Zhangqiu, Zhangqiu, Shandong 250200, P.R. China, Department of Oral Pendulum Medicine, People's Hospital of Zhangqiu, Zhangqiu, Shandong 250200, P.R. China, Pharmacy Intravenous Admixture Services, The Second Hospital of Shandong University, Jinan, Shandong 250033, P.R. China
Published online on: December 2, 2014 https://doi.org/10.3892/or.2014.3644
Pages: 783-791

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

This study was mainly focused on the development of a dual-ligand liposomal delivery system for targeting the delivery of paclitaxel (PTX) to lung cancer. The specific ligand peptide HAIYPRH (T7) and the cationic cell-penetrating peptide TAT were connected with phospholipid via a polyethylene glycol (PEG) spacer to prepare the dual-ligand liposomes (T7/TAT-LP-PTX). Physicochemical characterizations of T7/TAT-LP-PTX, such as particle size, ζ potential, morphology, encapsulation efficiency, and in vitro PTX release, were also evaluated. In the cellular uptake study, the T7/TAT-LP endocytosed by the A549 cells was 2.26‑, 3.48‑ and 8.56‑fold higher than TAT-LP, T7-LP and LP, respectively. The IC50 values of TAT-LP-PTX, T7-LP-PTX and LP-PTX were much higher than those of T7/TAT-LP-PTX, respectively. The homing specificity of T7/TAT-LP was evaluated on the tumor spheroids, which revealed that T7/TAT-LP was more efficaciously internalized in tumor cells than TAT-LP, T7-LP and LP, respectively. Compared to LP, TAT-LP and T7-LP, T7/TAT-LP showed the strongest cell uptake property, and the highest accumulation ability in tumor spheroids in vitro. In the in vivo study, the T7/TAT-LP-PTX exhibited the best inhibitory effect of tumor growth for A549-bearing mice. Collectively, these results suggested that T7/TAT-LP-PTX is a promising drug delivery system for the treatment of lung cancer.

View Figures

View References

1	Jinturkar KA, Anish C, Kumar MK, Bagchi T, Panda AK and Misra AR: Liposomal formulations of etoposide and docetaxel for p53 mediated enhanced cytotoxicity in lung cancer cell lines. Biomaterials. 33:2492–2507. 2012. View Article : Google Scholar
2	Sengupta S, Tyagi P, Velpandian T, et al: Etoposide encapsulated in positively charged liposomes: pharmacokinetic studies in mice and formulation stability studies. Pharmacol Res. 42:459–464. 2000. View Article : Google Scholar : PubMed/NCBI
3	Maeda H: Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. J Control Release. 164:138–144. 2012. View Article : Google Scholar : PubMed/NCBI
4	Tang J, Zhang L, Liu Y, et al: Synergistic targeted delivery of payload into tumor cells by dual-ligand liposomes co-modified with cholesterol anchored transferrin and TAT. Int J Pharm. 454:31–40. 2013. View Article : Google Scholar : PubMed/NCBI
5	Shmeeda H, Amitay Y, Gorin J, et al: Delivery of zoledronic acid encapsulated in folate-targeted liposome results in potent in vitro cytotoxic activity on tumor cells. J Control Release. 146:76–83. 2010. View Article : Google Scholar : PubMed/NCBI
6	Zhang Q, Tang J, Fu L, et al: A pH-responsive α-helical cell penetrating peptide-mediated liposomal delivery system. Biomaterials. 34:7980–7993. 2013. View Article : Google Scholar : PubMed/NCBI
7	Jiang X, Xin H, Gu J, et al: Solid tumor penetration by integrin-mediated pegylated poly(trimethylene carbonate) nanoparticles loaded with paclitaxel. Biomaterials. 34:1739–1746. 2013. View Article : Google Scholar
8	Han L, Huang R, Liu S, et al: Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors. Mol Pharm. 7:2156–2165. 2010. View Article : Google Scholar : PubMed/NCBI
9	Mei D, Gao H, Gong W, et al: Anti glioma effect of doxorubicin loaded liposomes modified with angiopep-2. Afr J Pharm Pharmacol. 5:409–414. 2011. View Article : Google Scholar
10	Gao H, Qian J, Yang Z, et al: Whole-cell SELEX aptamer-functionalised poly(ethyleneglycol)-poly(ɛ-caprolactone) nanoparticles for enhanced targeted glioblastoma therapy. Biomaterials. 33:6264–6272. 2012. View Article : Google Scholar : PubMed/NCBI
11	Zhang L, Chan JM, Gu FX, et al: Self-assembled lipid - polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano. 2:1696–1702. 2008. View Article : Google Scholar
12	Owen SC, Patel N, Logie J, et al: Targeting HER2⁺ breast cancer cells: lysosomal accumulation of anti-HER2 antibodies is influenced by antibody binding site and conjugation to polymeric nanoparticles. J Control Release. 172:395–404. 2013. View Article : Google Scholar : PubMed/NCBI
13	Rossiello R, Carriero MV and Giordano GG: Distribution of ferritin, transferrin and lactoferrin in breast carcinoma tissue. J Clin Pathol. 37:51–55. 1984. View Article : Google Scholar : PubMed/NCBI
14	Shindelman JE, Ortmeyer AE and Sussman HH: Demonstration of the transferrin receptor in human breast cancer tissue. Potential marker for identifying dividing cells. Int J Cancer. 27:329–334. 1981. View Article : Google Scholar : PubMed/NCBI
15	Han L, Li J, Huang S, et al: Peptide-conjugated polyamidoamine dendrimer as a nanoscale tumor-targeted T1 magnetic resonance imaging contrast agent. Biomaterials. 32:2989–2998. 2011. View Article : Google Scholar : PubMed/NCBI
16	Lee JH, Engler JA, Collawn JF and Moore BA: Receptor mediated uptake of peptides that bind the human transferrin receptor. Eur J Biochem. 268:2004–2012. 2001. View Article : Google Scholar : PubMed/NCBI
17	Oh S, Kim BJ, Singh NP, et al: Synthesis and anti-cancer activity of covalent conjugates of artemisinin and a transferrin-receptor targeting peptide. Cancer Lett. 274:33–39. 2009. View Article : Google Scholar
18	Sharma G, Modgil A, Sun C, Singh J, et al: Grafting of cell-penetrating peptide to receptor-targeted liposomes improves their transfection efficiency and transport across blood-brain barrier model. J Pharm Sci. 101:2468–2478. 2012. View Article : Google Scholar : PubMed/NCBI
19	Kibria G, Hatakeyama H, Ohga N, et al: Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery. J Control Release. 153:141–148. 2011. View Article : Google Scholar : PubMed/NCBI
20	Qin Y, Chen H, Zhang Q, et al: Liposome formulated with TAT-modified cholesterol for improving brain delivery and therapeutic efficacy on brain glioma in animals. Int J Pharm. 420:304–312. 2011. View Article : Google Scholar : PubMed/NCBI
21	Gupta B, Levchenko TS and Torchilin VP: Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv Drug Deliv Rev. 57:637–651. 2005. View Article : Google Scholar : PubMed/NCBI
22	Banks WA, Robinson SM, Nath A, et al: Permeability of the blood-brain barrier to HIV-1 Tat. Exp Neurol. 193:218–227. 2005. View Article : Google Scholar : PubMed/NCBI
23	Brooks H, Lebleu B and Vivès E: Tat peptide-mediated cellular delivery: back to basics. Adv Drug Deliv Rev. 57:559–577. 2005. View Article : Google Scholar : PubMed/NCBI
24	Torchilin VP, Rammohan R, Weissig V and Levchenko TS: TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proc Nat Acad Sci USA. 98:8786–8791. 2001. View Article : Google Scholar : PubMed/NCBI
25	Allen TM, Brandeis E, Hansen CB, et al: A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Biochim Biophys Acta. 1237:99–108. 1995. View Article : Google Scholar : PubMed/NCBI
26	Du S, Pan H, Lu W, et al: Cyclic Arg-Gly-Asp peptide-labeled liposomes for targeting drug therapy of hepatic fibrosis in rats. J Pharmacol Exp Ther. 322:560–568. 2007. View Article : Google Scholar : PubMed/NCBI
27	Li F, Sun J, Wang J, et al: Effect of hepatocyte growth factor encapsulated in targeted liposomes on liver cirrhosis. J Control Release. 131:77–82. 2008. View Article : Google Scholar : PubMed/NCBI
28	Gao LY, Liu XY, Chen CJ, et al: Core-shell type lipid/rPAA-Chol polymer hybrid nanoparticles for in vivo siRNA delivery. Biomaterials. 35:2066–2078. 2014. View Article : Google Scholar
29	McNeeley KM, Karathanasis E, Annapragada AV and Bellamkonda RV: Masking and triggered unmasking of targeting ligands on nanocarriers to improve drug delivery to brain tumors. Biomaterials. 30:3986–3995. 2009. View Article : Google Scholar : PubMed/NCBI
30	Kuai R, Yuan W, Qin Y, et al: Efficient delivery of payload into tumor cells in a controlled manner by TAT and thiolytic cleavable PEG co-modified liposomes. Mol Pharm. 7:1816–1826. 2010. View Article : Google Scholar : PubMed/NCBI
31	Jiang T, Zhang Z, Zhang Y, et al: Dual-functional liposomes based on pH-responsive cell-penetrating peptide and hyaluronic acid for tumor-targeted anticancer drug delivery. Biomaterials. 33:9246–9258. 2012. View Article : Google Scholar : PubMed/NCBI
32	Maeda N, Takeuchi Y, Takada M, et al: Anti-neovascular therapy by use of tumor neovasculature-targeted long-circulating liposome. J Control Release. 100:41–52. 2004. View Article : Google Scholar : PubMed/NCBI
33	Yang T, Choi MK, Cui FD, Kim JS, et al: Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome. J Control Release. 120:169–177. 2007. View Article : Google Scholar : PubMed/NCBI
34	Liu Y, Li K, Pan J, et al: Folic acid conjugated nanoparticles of mixed lipid monolayer shell and biodegradable polymer core for targeted delivery of Docetaxel. Biomaterials. 31:330–338. 2010. View Article : Google Scholar
35	Lewis CE and Pollard JW: Distinct role of macrophages in different tumor microenvironments. Cancer Res. 66:605–612. 2006. View Article : Google Scholar : PubMed/NCBI
36	Fukumura D, Xu L, Chen Y, Gohongi T, Seed B and Jain RK: Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res. 61:6020–6024. 2001.PubMed/NCBI
37	Jain RK: Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev. 46:149–168. 2001. View Article : Google Scholar : PubMed/NCBI
38	Kobayashi H, Man S, Graham CH, et al: Acquired multicellular-mediated resistance to alkylating agents in cancer. Proc Natl Acad Sci USA. 90:3294–3298. 1993. View Article : Google Scholar : PubMed/NCBI
39	Du J, Lu WL, Ying X, et al: Dual-targeting topotecan liposomes modified with tamoxifen and wheat germ agglutinin significantly improve drug transport across the blood-brain barrier and survival of brain tumor-bearing animals. Mol Pharm. 6:905–917. 2009. View Article : Google Scholar : PubMed/NCBI